gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Protein phosphatase 2, regulatory subunit A, alpha

PPP2R1A, PP2A subunit A PR65-alpha isoform, medium tumor antigen-associated 61-kDa protein
This gene encodes a constant regulatory subunit of protein phosphatase 2. Protein phosphatase 2 is one of the four major Ser/Thr phosphatases, and it is implicated in the negative control of cell growth and division. It consists of a common heteromeric core enzyme, which is composed of a catalytic subunit and a constant regulatory subunit, that associates with a variety of regulatory subunits. The constant regulatory subunit A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit. This gene encodes an alpha isoform of the constant regulatory subunit A. Alternatively spliced transcript variants have been described. [provided by RefSeq, Apr 2010] (from NCBI)
Top mentioned proteins: PP2A, PI3K, PTEN, p53, beta Catenin
Papers on PPP2R1A
A novel somatic MAPK1 mutation in primary ovarian mixed germ cell tumors.
Huang et al., Nanchang, China. In Oncol Rep, Feb 2016
Additionally, mutations in protein phosphatase 2 regulatory subunit α (PPP2R1A), ring finger protein 43 (RNF43), DNA directed polymerase ε (POLE1), ribonuclease type III (DICER1), CCCTC‑binding factor (CTCF), ribosomal protein L22 (RPL22), DNA methyltransferase 3α (DNMT3A), transformation/transcription domain‑associated protein (TRRAP), isocitrate dehydrogenase (IDH)1 and IDH2 were not detected in ovarian mixed germ cell tumors, implicating these genetic alterations may be not associated with MAPK1 mutation in the development of this malignancy.
Genetic alterations in endometrial cancer by targeted next-generation sequencing.
Chang et al., Taiwan. In Exp Mol Pathol, Dec 2015
The 21 genes comprised 8 tumor suppressor candidates (ATM, MSH2, PIK3R1, PTCH1, PTEN, TET2, TP53, and TSC1) and 13 oncogene candidates (ALK, BCL9, CTNNB1, ERBB2, FGFR2, FLT3, HNF1A, KIT, MTOR, PDGFRA, PPP2R1A, PTPN11, and SF3B1).
Comprehensive assessment of cancer missense mutation clustering in protein structures.
Getz et al., Cambridge, United States. In Proc Natl Acad Sci U S A, Nov 2015
Analysis of interaction interfaces revealed enrichment of mutations in the interfaces between FBXW7-CCNE1, HRAS-RASA1, CUL4B-CAND1, OGT-HCFC1, PPP2R1A-PPP2R5C/PPP2R2A, DICER1-Mg2+, MAX-DNA, SRSF2-RNA, and others.
B56δ-related protein phosphatase 2A dysfunction identified in patients with intellectual disability.
Janssens et al., In J Clin Invest, Sep 2015
Five patients had mutations in the PPP2R1A-encoded scaffolding Aα subunit, with the same R182W mutation in 3 individuals.
Mutation spectrum in the Wnt/β-catenin signaling pathway in gastric fundic gland-associated neoplasms/polyps.
Yao et al., Tokyo, Japan. In Virchows Arch, Jul 2015
We also examined β-catenin expression and the mutation spectrum of PPP2R1A and Wnt pathway genes in 11 cases of GD-CCP, 25 cases of gastric polyps of fundic gland type (GPs-FG), and 21 cases of GPs-FG with dysplasia (GP-FGD).
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.
Creutzberg et al., Leiden, Netherlands. In Mod Pathol, Jun 2015
Furthermore, DNA was analyzed for hotspot mutations in 13 additional genes (BRAF, CDKNA2, CTNNB1, FBXW7, FGFR2, FGFR3, FOXL2, HRAS, KRAS, NRAS, PIK3CA, PPP2R1A, and PTEN) and protein expression of ER, PR, PTEN, and ARID1a was analyzed.
Targeted mutation analysis of endometrial clear cell carcinoma.
Lee et al., Vancouver, Canada. In Histopathology, Apr 2015
Two tumours displayed a prototypical serous carcinoma mutation profile (concurrent TP53 and PPP2R1A mutations, without PTEN, CTNNB1 or ARID1A mutation).
Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis.
Pasqualini et al., Dublin, Ireland. In Proc Natl Acad Sci U S A, Mar 2015
Our results identified expression of the phosphatase 2 regulatory subunit A, α-isoform (PPP2R1A) on the cell surfaces of both melanoma cells and lymphatic endothelial cells.
CRL4-DCAF1 ubiquitin E3 ligase directs protein phosphatase 2A degradation to control oocyte meiotic maturation.
Fan et al., Hangzhou, China. In Nat Commun, 2014
Moreover, combined deletion of Ppp2r1a rescues the meiotic defects caused by DDB1/DCAF1 deficiency.
Role of "oncogenic nexus" of CIP2A in breast oncogenesis: how does it work?
Dey et al., Sioux Falls, United States. In Am J Cancer Res, 2014
OncoPrints (c-BioPortal) showed alterations (%) of regulatory subunits genes of PP2A (PPP2R1A and PPP2R1B) along with alterations of CIP2A in breast invasive carcinoma (TCGA, Nature 2012 & TCGA, Provisional).
Chronic sleep deprivation-induced proteome changes in astrocytes of the rat hypothalamus.
Suk et al., Taegu, South Korea. In J Proteome Res, 2014
PPP2R1A, RTN4, VAMP-2, LGI-1, and SLC17A7 were identified and validated as the main targets of SD in astrocytes.
[Endometriosis-related ovarian tumors].
Ulrich et al., Mannheim, Germany. In Pathologe, 2014
Cases of clear cell carcinoma have been characterized by mutations of ARID1a gene, PIK3CA and less frequently PPP2R1A and KRAS.
Integrative analysis of the transcriptome and targetome identifies the regulatory network of miR-16: an inhibitory role against the activation of hepatic stellate cells.
Fang et al., Shanghai, China. In Biomed Mater Eng, 2013
Eight targets in the targetome (Map2k1, Bmpr1b, Nf1, Pik3r3, Ppp2r1a, Prkca, Smad2, and Sos2) served as key regulatory network nodes that mediate miR-16 action.
Identification and functional analyses of polymorphism haplotypes of protein phosphatase 2A-Aα gene promoter.
Lin et al., Guangzhou, China. In Mutat Res, 2011
Our findings suggest that functional genetic variants in the proximal promoter of the PP2A-Aalpha gene and their haplotypes are critical in the regulation of transcriptional activation.
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.
Shih et al., Baltimore, United States. In Hum Pathol, 2011
They are generally indolent, present in stage I (tumor confined to the ovary), and are characterized by specific mutations, including KRAS, BRAF, ERBB2, CTNNB1, PTEN, PIK3CA, ARID1A, and PPP2R1A, which target specific cell signaling pathways.
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
Huntsman et al., Vancouver, Canada. In J Pathol, 2011
identified somatic missense mutations in 40.8% of high-grade serous endometrial tumours and 5% of endometrial endometrioid carcinomas; mutations identified in ovarian tumours at lower frequencies;no mutations found in high- or low-grade serous carcinoma
Somatic mutations of PPP2R1A in ovarian and uterine carcinomas.
Wang et al., Baltimore, United States. In Am J Pathol, 2011
PPP2R1A somatic mutations occur in certain types of uterine and ovarian neoplastic lesions, especially uterine serous carcinomas
Dephosphorylation of Carma1 by PP2A negatively regulates T-cell activation.
Krappmann et al., München, Germany. In Embo J, 2011
PP2A-mediated dephosphorylation of Carma1 is a critical step to limit T-cell activation and effector cytokine production.
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Papadopoulos et al., Baltimore, United States. In Science, 2010
genes mutated in ovarian clear cell carcinoma(OCCC);data suggest PPP2R1A functions as an oncogene and ARID1A as tumor-suppressor gene; in 42 OCCCs, 7% had mutations in PPP2R1A and 57% in ARID1A; suggests aberrant chromatin remodeling contributes to OCCC
share on facebooktweetadd +1mail to friends